Polarityte 

$0.24
34
-$0-0.82% Thursday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
1.74M
P/E Ratio
-0.32
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Jan 16
$50.33
Jan 16
$8.39
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

9AugExpected
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
-2.75
-1.84
-0.92
-0.01
Expected EPS
-0.55
Actual EPS
N/A

Financials

-962.29%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
814,000Revenue
-7.83MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PTE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Consumer Durables
Recreational Products
Manufacturing
Biological Product (except Diagnostic) Manufacturing
PolarityTE, Inc., a biotechnology and regenerative biomaterials company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Show more...
CEO
David Seaburg
Employees
80
Country
US
ISIN
US7310942070
WKN
000A3DLAY

Listings

0 Comments

Share your thoughts

FAQ

What is Polarityte stock price today?
The current price of PTE is $0.24 USD — it has decreased by -0.82% in the past 24 hours. Watch Polarityte stock price performance more closely on the chart.
What is Polarityte stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Polarityte stocks are traded under the ticker PTE.
What is Polarityte market cap?
Today Polarityte has the market capitalization of 1.74M
What is Polarityte revenue for the last year?
Polarityte revenue for the last year amounts to 814,000 USD.
What is Polarityte net income for the last year?
PTE net income for the last year is -7.83M USD.
Does Polarityte pay dividends?
Yes, PTE dividends are paid en. The last dividend per share was 50.33 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Polarityte have?
As of April 04, 2026, the company has 80 employees.
In which sector is Polarityte located?
Polarityte operates in the Manufacturing sector.
When did Polarityte complete a stock split?
The last stock split for Polarityte was on May 17, 2022 with a ratio of 1:25.
Where is Polarityte headquartered?
Polarityte is headquartered in Salt Lake City, US.